Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) rose 7.1% during trading on Tuesday . The stock traded as high as $10.71 and last traded at $10.99. Approximately 22,690 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 273,751 shares. The stock had previously closed at $10.26.
Analyst Upgrades and Downgrades
TYRA has been the subject of a number of analyst reports. Wedbush reaffirmed an "outperform" rating and issued a $30.00 price target on shares of Tyra Biosciences in a report on Friday, March 28th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Monday, March 31st. Finally, Piper Sandler assumed coverage on shares of Tyra Biosciences in a report on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $30.83.
Read Our Latest Stock Analysis on TYRA
Tyra Biosciences Stock Performance
The firm has a market cap of $553.73 million, a PE ratio of -6.48 and a beta of 1.07. The firm's 50 day moving average price is $9.57 and its two-hundred day moving average price is $11.98.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. On average, analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.
Institutional Trading of Tyra Biosciences
Hedge funds and other institutional investors have recently made changes to their positions in the company. Alta Partners Management Company L.P. acquired a new position in Tyra Biosciences during the fourth quarter worth about $56,716,000. Boxer Capital Management LLC purchased a new stake in Tyra Biosciences in the fourth quarter valued at approximately $28,185,000. Vestal Point Capital LP grew its holdings in Tyra Biosciences by 190.9% in the first quarter. Vestal Point Capital LP now owns 2,879,829 shares of the company's stock valued at $26,782,000 after purchasing an additional 1,889,829 shares during the period. Farallon Capital Management LLC purchased a new stake in Tyra Biosciences during the fourth quarter worth approximately $13,914,000. Finally, Orbimed Advisors LLC grew its stake in Tyra Biosciences by 91.3% during the fourth quarter. Orbimed Advisors LLC now owns 1,470,086 shares of the company's stock worth $20,434,000 after buying an additional 701,448 shares during the period. Hedge funds and other institutional investors own 84.14% of the company's stock.
Tyra Biosciences Company Profile
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Articles
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
